Additionally, ALKBH5 was prominently downregulated in NSCLC patients, and its upregulation has been shown to inhibit tumor progression by promoting ferroptosis through the suppression of SLC7A11 expression. This evidence concerns the gene SLC7A11 and neoplasm.